TransMedics Q1 revenue $41.6M (+162% YoY); raises FY23 guidance to $160-170M

TransMedics Group, Inc.

2023-Q1 EPS reported -$0.08 revenue$41,554,000

Q1 2023 revenue $41.6M (+162% YoY from $15.9M) driven by NOP adoption and OCS Liver/Heart sales.
Gross margin 69% vs 76% in Q1 2022 and 66% in Q4 2022.
Net loss improved to $2.6M from $10.6M in Q1 2022.
Operating expenses $30.9M (incl. $3.9M stock comp) vs $21.5M (incl. $2.3M) in prior year.
FY2023 revenue guidance raised to $160-170M (71-82% growth) from prior $138-145M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TransMedics Group, Inc. reported the quarter ended March 31, 2023 results: revenue $41.6 million, net income $2.6 million, EPS $(0.34) per diluted share. Guidance raised.

Period: the quarter ended March 31, 2023
Revenue: $41.6 million
Net income: $2.6 million
EPS: $(0.34) per diluted share
Guidance: raised
Result: reported results

Exact text from the filing

TransMedics Reports First Quarter 2023 Financial Results Andover, Mass. – May 1, 2023 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2023. Recent Highlights ▪ Net revenue of $41.6 million in the first quarter of 2023, a 162% increase compared to the first quarter of 2022

View on SEC.gov

Browse all earnings releases →

TransMedics Group, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-016245

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.